Therapy-related leukemia associated with chemotherapy, particularly alkylating agents and topoisomerase II inhibitors, are being reported with increasing frequency in the literature mainly after breast cancer. We also observed an increasing number of such leukemias in the data base of the specialized registry of hematological malignancies of the Cô te d'Or department. Between 1980 and 1998, 156 AML and RAEB-t were registered in women in Cô te d'Or. Among them, 12 occurred in women with breast cancer history (7.7%). Analysis by period of time shows a significant increase in the proportion of therapyrelated leukemia secondary to breast cancer (P Ͻ 0.02). Chemotherapy including topoisomerase II inhibitors was used in 10 cases in which mitoxantrone was used in eight cases. In these eight cases, leukemia had clinical and biological characteristics usually described with topoisomerase II inhibitors but 44% were promyelocytic sub-type with the t(15;17) specific karyotypic abnormality. These data on a well-defined population demonstrate the increased proportion of therapy-related leukemia secondary to breast cancer, probably due to the use of mitoxantrone. Leukemia
Introduction
As survival following treatment for various malignancies continues to improve, increasing attention must be focused on the potential long-term outcome. Therapy-related leukemia associated with radiotherapy and/or chemotherapy, particularly alkylating agents and topoisomerase II inhibitors, are being reported with increasing frequency. [1] [2] [3] The most frequently occurring types of therapy-related leukemia are acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 4 Their incidence varies greatly among studies because of the therapeutic schedule, the number of cases and the primary cancer under treatment. 5 Hodgkin's disease is the most frequent primary diagnosis reported but there is an increasing number of breast cancer cases in the literature. 3, [6] [7] [8] [9] We also observed an increasing number of therapy-related leukemia secondary to breast cancer in the data base of the specialized registry of hematological malignancies of the Cô te d'Or department. These leukemia appear to be mainly of promyelocytic type and seem to be related to the mitoxantrone regimen.
Materials and methods
The Cô te d'Or registry of hematological malignancies, created in 1980, 10 covers a population of 493 932 inhabitants, according to the 1990 census. Information was collected from public and private biological laboratories, and university and local (both public and private) hospital departments. The study included incident cases of AML and refractory anemia with excess of blasts in transformation (RAEB-t), diagnosed between 1980 and 1998, among women between 20 and 84 years old, in the department of Cô te d'Or. Clinical and biological data were recorded for all cases. The diagnosis of AML and of RAEB-t was made according to the French-American-British (FAB) classification criteria. 11, 12 Among MDS, only RAEB-t were included because they have always been considered close to AML and they are now considered as the same entity. 13 Cytogenetic studies were performed on bone marrow cells, and chromosomes were identified by standard techniques including RHG, GTG banding and classified according to the International System for Cytogenetic Nomenclature. 14 All cases with solid tumor history, including breast cancer, were identified and the diagnosis of primary breast cancer and the treatment used were checked with medical records.
The time trend in the percentage of patients with breast cancer was tested under the assumption of an exponential model. Fisher's exact test was used to compare the percentage of patients with promyelocytic leukemia depending on whether they had breast cancer history or not.
Results
Between 1980 and 1998, 156 AML and RAEB-t were diagnosed in women in the Cô te d'Or department. Among them, 12 occurred in women with breast cancer history (7.7%). A history of another solid tumor was found in nine cases (5.7%) in which one received chemotherapy, three received radiotherapy and one had surgery alone.
Main clinical and biological features of the 12 cases secondary to breast cancer are presented in Table 1 . All patients underwent surgical treatment and radiotherapy. Patients 1 to 10 also received chemotherapy either as adjuvant treatment (patients 1-7, 9 and 10) or as first-line treatment for local and/or distant recurrence (patients 8 and 9). In nine of the patients who received chemotherapy, mitoxantrone was included as first-line treatment in eight cases (patients [1] [2] [3] [4] [5] [6] [7] [8] and as treatment of a metastatic recurrence in one case (patient 9). The median latency between the onset of mitoxantrone use and the secondary leukemia was 15 months (range, 11-40). Patient 9 received epidoxorubicin then mitoxantrone, and in patient 10, epidoxorubicin alone was used.
According to the FAB classification, the M3 AML subtype represents 44% (4/9) of secondary leukemia to breast cancer treated with mitoxantrone instead of 7% (10/145) of other AML in women (P Ͻ 0.004). Other secondary leukemias to breast cancer were two RAEB-t, one M4, one M4 Eo and one M0.
Cytogenetic analysis was performed in 8/9 patients and the classical t(15;17)(q22;q21) was present in all M3 cases which were treated with all-trans retinoic acid regimen. Three of them were alive, but patient 2 died during the induction phase of the treatment. In the M4 Eo case the specific inversion (inv16)(p13;q32) was found and both patients who had epidoxorubicin (patients 9 and 10) had a translocation t(11;19)(q23;p13.1).
In our registry, three cases of therapy-related leukemia secondary to a solid tumor were registered in women before 1986. The first case secondary to breast cancer was registered in 1986 and the first case secondary to breast cancer treated by mitoxantrone was detected in 1989. In the period 1996-1998, there were six cases secondary to breast cancer (26%: 6/23) in which five were treated by mitoxantrone, ie 22% of all the leukemias (5/23) ( Figure 1 ). There is a significant increase in the proportion of therapy-related leukemia secondary to breast cancer (P Ͻ 0.02).
Discussion
Therapy-related leukemia appears to be one of the most serious problems in the long-term outcome of malignancies, and women with breast cancer are a known population at increased risk of therapy-leukemia. 5 Since the first leukemia secondary to breast cancer registered in 1986, their proportion has regularly increased and in the period 1996-1998, they represented, more than a quarter (6/23) of all leukemias in the female population. Our attention was particularly drawn to the increase in cases treated by topoisomerase-II inhibitors as the chemotherapeutic drug.
Analysis of the medical history of 10 cases which received chemotherapy revealed that topoisomerase-II inhibitors were used in all cases: mitoxantrone alone in eight cases and epidoxorubicin in one case; in patient 9 both were used in succession. Futhermore they exhibited characteristics close to those of leukemia related to topoisomerase-II inhibitors: a short latency period, an acute onset rather than an initial myelodysplastic presentation, 7, 15 equilibrated translocation in six cases, of which five were specific of FAB subtype: t(15;17)(q22;q21) in M3 sub-type and inv(16)(p13;q22) in M4Eo. 16, 17 The initial translocation described in topoisomerase-II inhibitor-related leukemia concerned chromosome 11q23 involving the mixed lineage leukemia gene (MML), 1 which was present in two cases.
Because mitoxantrone is rarely used as a single agent, it is difficult to ascertain its causative role. Nevertheless some characteristics are in favour of this role. (1) In France, the use of mitoxantrone was authorized in 1985 and first French reports of mitoxantrone-related leukemia in breast cancer were made in 1992 18 and in 1996, 8 which agree with our observation. (2) Mitoxantrone alone was used in patient 1. In eight patients mitoxantrone has been associated with cyclophosphamide which is an alkylating agent, but leukemia secondary to these molecules exhibited other characteristics. 19, 20 Mitoxantrone has also been associated with 5FU and vincaalkaloids, but they are not known to have leukemogenic effects.
One of the most important findings of the present report is the very high proportion of promyelocytic leukemia in patients who received mitoxantrone (4/9). AML subtypes mainly observed with topoisomerase-II inhibitors are M4 or M5, 9 and 12 cases of M3 sub-type therapy-related leukemia secondary to mitoxantrone have been reported. 17, 18 Clinical, cytological and cytogenetical characteristics of such cases do not seem to differ from de novo M3 AML. As M3 AML can benefit from an effective treatment with all-trans retinoic acid and as we observed that in three out of four M3 cases the response to induction was good and the survival can be long (4 years in case 1), it is a favorable point.
Our data on a well-defined population demonstrate the increased proportion of therapy-related leukemia secondary to breast cancer, probably due to the use of mitoxantrone. The study is ongoing to evaluate the relative risk of AML in the population of women with breast cancer from the data base of the registry of breast cancer in the Cô te d'Or department. Nevertheless it is a matter of urgency to alert the medical community and the authorities of the discovery of new consequences of solid tumor treatment.
